)
Anthem Biosciences (ANTHEM) investor relations material
Anthem Biosciences Q2 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
H1 FY2026 consolidated revenue reached ₹10,902.36 million, with strong CRDMO growth and EBITDA margin of 41.4%.
PAT for H1 FY2026 was ₹3,092.18 million, with a PAT margin of 26.6%.
Net cash position improved to ₹9,934 million as of September 30, 2025.
Management remains confident in sustaining growth and long-term value creation.
Unaudited financials for H1 FY26 were approved and reviewed by the Board and Audit Committee.
Financial highlights
H1 FY26 revenue from operations was ₹10,902.36 million, up 26.3% year-over-year.
H1 FY26 EBITDA was ₹4,800 million, with a margin of 41.4%.
H1 FY26 PAT was ₹3,092.18 million, with a margin of 26.6%.
Basic EPS (consolidated) for H1 FY26 was ₹5.52.
Net cash from operating activities (consolidated) for H1 FY26 was ₹4,025.17 million.
Outlook and guidance
Specialty ingredients expected to recover in H2 as new capacity comes online.
EBITDA margins are expected to remain at the upper end of the 36–37% guidance for the full year.
Management targets maintaining a 20% CAGR, with quarter-to-quarter variations possible.
IPO proceeds and ESOP allotments have strengthened the equity base.
Management expresses confidence in sustaining growth momentum and delivering long-term stakeholder value.
- TimeTickerHeadlineOpen
- SDST
Development-stage lithium refiner registers shares for resale amid high risk and capital needs. - DAC
Q2 2025 saw revenue growth, high charter coverage, and strong liquidity despite rising costs. - OCSL
Net investment income was $36.7M ($0.42/share) as NAV fell to $16.30 and a $0.40 dividend was declared. - NUWE
Registering 4.28M shares for resale, proceeds from warrant exercises support working capital. - WBD
Board selects Netflix merger for streaming and studios, with Discovery Global to be spun off. - TTWO
Q3 FY2026 net bookings up 28% year-over-year; outlook raised on digital and mobile strength. - SLGN
Record 2025 growth in key segments, with continued earnings and cash flow gains expected in 2026. - LITE
Q2 FY2026 revenue up 65.5% to $665.5M, margins and outlook strong, OCS backlog tops $400M. - HEBA
Profit and NOI rose sharply in 2025, with strong margins and record-low vacancies. - TOBII
Cost savings and a DMS deal offset weak sales and large write-offs, boosting cash flow.
Next Anthem Biosciences earnings date
Next Anthem Biosciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)